The Use of Procalcitonin/Albumin Ratio in Prediction of 30-day Mortality in Intensive Care Patients.

Introduction: We aimed to compare the procalcitonin/albumin ratio, with the previously proven APACHE II score, which is easily applicable in predicting 30-day mortality rates. Materials and Methods: Of the 184 patients, >18 aged, hospitalized between December, 2021-April, 2022 was performed. Gender, comorbidity, mortality within 30 days, hospitalization days, procalcitonin, albumin, CRP and APACHE II scores were obtained. Procalcitonin/albumin and CRP/ albumin values were created by dividing these two values. The group with mortality within 30 days was determined as the main group, while the group without mortality within 30 days was determined as the control group. These values were compared with the APACHE II score values in predicting mortality, and specificity and sensitivity were determined. Results: Of the 184 patients included in the study, 47.8% were female and 52.2% were male, with a mean age of 65.5±18.3 years (median 69). There was no significant difference in age and gender in the group with and without mortality within 30 days. The 30-day mortality rate was 37% (n=68). Albumin value was significantly lower in the group with mortality within 30 days compared to the group without mortality; procalcitonin, procalcitonin/albumin, APACHE II value at 30 days were significantly higher than the group without mortality. CRP, CRP/albumin value did not differ significantly. Significant efficacy of albumin, procalcitonin, procalcitonin/albumin 0.160 cut-off value and APACHE II were observed in predicting patients with and without mortality within 30 days. Significant effectiveness of procalcitonin/albumin value was observed. Conclusion: It was found that the procalcitonin/albumin ratio was significantly associated with the estimation of 30-day mortality in patients hospitalized in ICU. [ABSTRACT FROM AUTHOR]